Formosa Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Formosa Laboratories wird voraussichtlich ein Umsatzwachstum verzeichnen at 6.8% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	48.0%
Wachstumsrate der Einnahmen	6.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Formosa Laboratories, Inc. (TWSE:4746)

Sep 20

Investors Can Find Comfort In Formosa Laboratories' (TWSE:4746) Earnings Quality

May 22

Benign Growth For Formosa Laboratories, Inc. (TWSE:4746) Underpins Its Share Price

Apr 19

Here's Why Formosa Laboratories (TPE:4746) Has A Meaningful Debt Burden

Apr 19

Does Formosa Laboratories, Inc.'s (TPE:4746) Weak Fundamentals Mean A Downturn In Its Stock Should Be Expected?

Mar 16

What Type Of Returns Would Formosa Laboratories'(TPE:4746) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 08

Formosa Laboratories (TPE:4746) Is Making Moderate Use Of Debt

Jan 11

Formosa Laboratories's (TPE:4746) Earnings Are Growing But Is There More To The Story?

Dec 13

Gewinn- und Umsatzwachstumsprognosen

TWSE:4746 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	5,162	N/A	773	1,270	1
12/31/2024	4,727	706	481	978	1
6/30/2024	4,690	256	396	963	N/A
3/31/2024	4,563	55	401	988	N/A
12/31/2023	4,360	126	286	827	N/A
9/30/2023	4,216	270	233	728	N/A
6/30/2023	4,111	876	91	534	N/A
3/31/2023	3,863	785	250	658	N/A
12/31/2022	3,766	409	203	643	N/A
9/30/2022	3,586	-94	-72	349	N/A
6/30/2022	3,252	-970	-162	315	N/A
3/31/2022	3,241	-217	-268	350	N/A
12/31/2021	3,142	1,249	-203	311	N/A
9/30/2021	3,064	1,293	-196	356	N/A
6/30/2021	3,189	1,778	-93	491	N/A
3/31/2021	3,149	1,568	-370	400	N/A
12/31/2020	3,075	400	-536	475	N/A
9/30/2020	2,987	460	-809	534	N/A
6/30/2020	2,962	531	-1,103	360	N/A
3/31/2020	2,768	-122	-850	489	N/A
12/31/2019	2,760	12	-1,134	287	N/A
9/30/2019	2,735	188	-1,121	83	N/A
6/30/2019	2,630	-108	-1,137	0	N/A
3/31/2019	2,729	38	-1,202	-123	N/A
12/31/2018	2,688	177	-1,082	-81	N/A
9/30/2018	2,659	103	-814	66	N/A
6/30/2018	2,600	266	-605	140	N/A
3/31/2018	2,575	358	N/A	136	N/A
12/31/2017	2,539	239	N/A	395	N/A
9/30/2017	2,651	347	N/A	672	N/A
6/30/2017	2,793	404	N/A	889	N/A
3/31/2017	3,022	431	N/A	1,102	N/A
12/31/2016	3,189	483	N/A	1,110	N/A
9/30/2016	3,280	457	N/A	849	N/A
6/30/2016	3,225	474	N/A	628	N/A
3/31/2016	2,813	345	N/A	404	N/A
12/31/2015	2,597	282	N/A	255	N/A
9/30/2015	2,252	231	N/A	300	N/A
6/30/2015	2,115	206	N/A	286	N/A
3/31/2015	2,416	248	N/A	340	N/A
12/31/2014	2,496	262	N/A	280	N/A
9/30/2014	2,710	252	N/A	268	N/A
6/30/2014	2,852	207	N/A	289	N/A
3/31/2014	2,845	150	N/A	-123	N/A
12/31/2013	2,474	-69	N/A	32	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 4746 über der Sparquote liegt (1%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 4746 schneller wachsen werden als der Markt TW

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 4746 in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 4746Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt TW (12.3% pro Jahr).

Hohe Wachstumseinnahmen: 4746Die Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 4746 in 3 Jahren voraussichtlich hoch sein wird

Formosa Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to NT$55.00

Recent updates

Investor sentiment improves as stock rises 16%

Risks To Shareholder Returns Are Elevated At These Prices For Formosa Laboratories, Inc. (TWSE:4746)

Second quarter 2024 earnings released: EPS: NT$2.36 (vs NT$0.69 in 2Q 2023)

Formosa Laboratories, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Formosa Laboratories, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Dividend increased to NT$2.00

Formosa Laboratories, Inc. Announces Common Stock Dividend Distribution, Payable on September 12, 2024

Formosa Laboratories, Inc. (TWSE : 4746) acquired SynChem, Inc.

Investors Can Find Comfort In Formosa Laboratories' (TWSE:4746) Earnings Quality

First quarter 2024 earnings released: NT$0.80 loss per share (vs NT$0.21 loss in 1Q 2023)

Formosa Laboratories, Inc. to Report Q1, 2024 Results on May 09, 2024

Formosa Laboratories, Inc. to Report Q1, 2024 Results on May 09, 2024

Benign Growth For Formosa Laboratories, Inc. (TWSE:4746) Underpins Its Share Price

Formosa Laboratories, Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 15%

New minor risk - Earnings quality

Investor sentiment improves as stock rises 18%

Formosa Laboratories, Inc. Announces Change of Members of the Sustainable Development Committee

Upcoming dividend of NT$1.00 per share at 1.2% yield

Second quarter 2023 earnings released: EPS: NT$0.69 (vs NT$0.071 loss in 2Q 2022)

Formosa Laboratories, Inc. Appoints Lin Chien-Fei as Chief Information Security Officer

Formosa Laboratories, Inc. Announces Cash Dividend, Payable on September 22, 2023

Formosa Laboratories, Inc. Approves Independent Directors Elections

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: NT$3.40 (vs NT$10.92 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$4.09 (vs NT$3.20 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.07 loss per share (vs NT$6.86 profit in 2Q 2021)

Upcoming dividend of NT$2.00 per share

First quarter 2022 earnings released: NT$3.33 loss per share (vs NT$9.84 profit in 1Q 2021)

Price target decreased to NT$55.00

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: NT$3.20 loss per share (vs NT$0.93 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$6.86 (vs NT$4.99 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$9.84 (vs NT$1.03 loss in 1Q 2020)

Here's Why Formosa Laboratories (TPE:4746) Has A Meaningful Debt Burden

Investor sentiment improved over the past week

Does Formosa Laboratories, Inc.'s (TPE:4746) Weak Fundamentals Mean A Downturn In Its Stock Should Be Expected?

Full year 2020 earnings released: EPS NT$3.78 (vs NT$0.12 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: NT$52.80

What Type Of Returns Would Formosa Laboratories'(TPE:4746) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Formosa Laboratories (TPE:4746) Is Making Moderate Use Of Debt

Formosa Laboratories's (TPE:4746) Earnings Are Growing But Is There More To The Story?

New 90-day low: NT$47.80

Third quarter 2020 earnings released: EPS NT$0.93

New 90-day low: NT$48.40

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken